Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01156090 · ClinicalTrials.gov registry record
A Retrospective Cohort Study of Infusion Reactions Due to Vectibix
A clinical trial, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- 141
- Enrollment target
NCT01156090: Completed study, sponsored by SCRI Development Innovations.
NCT01156090 is a clinical trial that has completed, run by SCRI Development Innovations. The registered enrollment target is 141 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01156090 has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- 141 participants
- Enrollment target
Study Summary
The purpose of this study is to identify approximately 100 - 150 patients who have received Vectibix (Panitumumab) in offices and clinics located in Tennessee, North Carolina, South Carolina, and North Georgia from February 2004 - April 2009. Information regarding the incidence and severity of hypersensitivity infusion reactions to Vectibix (Panitumumab)will be captured. In patients who experienced hypersensitivity reactions, the following information will also be collected: premedication, treatment cycle symptoms that were experienced during chemotherapy, changes required in subsequent Vectibix (Panitumumab) or chemotherapy treatment, and outcome of the hypersensitivity reaction.
Primary Outcome
To determine the rate of Vectibix (Panitumumab)-related infusion reactions (CTCAE v3.0 grade I-IV) in geographic areas of the United States associated with a high rate of Erbitux-related infusion reactions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-01 |
What the finished NCT01156090 record still lists
NCT01156090 is an observational study that tracks outcomes without assigning an intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01156090 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01156090 about?
NCT01156090 is a clinical study titled "A Retrospective Cohort Study of Infusion Reactions Due to Vectibix". The purpose of this study is to identify approximately 100 - 150 patients who have received Vectibix (Panitumumab) in offices and clinics located in Tennessee, North Carolina, South Carolina, and North Georgia from February 2004 - April 2009. Information regarding the incidence and severity of hyper...
What is the current status of trial NCT01156090?
This trial is currently completed. The enrollment target is 141 participants. The study started on 2010-06. Estimated completion is 2013-01.
Who is sponsoring clinical trial NCT01156090?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia